Physician profile
Michael D Meyer
NPI 1477964005
$13,090.60
in general payments reported to CMS, 2019-2025
34 companies · $3,103 in 2025
The $3,103 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,084 · 2020: $1,001 · 2021: $1,042 · 2022: $885 · 2023: $2,280 · 2024: $2,697 · 2025: $3,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,539 · Consulting Fee: $430 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,539.05 |
| Consulting Fee | $430.00 |
| Education | $110.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,925.32 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,367.94 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Sun Pharmaceutical Industries INC. | $1,012.52 | 2019-2024 | Blu-U, Ilumya, Odomzo |
| Regeneron Healthcare Solutions, INC. | $843.31 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $802.04 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $792.96 | 2021-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $757.44 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $738.73 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $599.65 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $558.42 | 2019-2025 | |
| Amgen INC. | $505.89 | 2020-2025 | Otezla, Otezla |
| Vyne Pharmaceuticals INC. | $461.02 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $428.17 | 2019-2025 | |
| Pfizer INC. | $390.30 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $269.97 | 2023-2025 | Sotyktu |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $235.43 | 2019-2025 | Seysara, Klisyri |
| Dermavant Sciences, INC. | $204.18 | 2023-2024 | Vtama |
| Dermira, INC. | $170.65 | 2019-2021 | |
| Ucb, INC. | $163.68 | 2020-2025 | Bimzelx |
| Organon LLC | $140.52 | 2025 | Vtama |
| Biofrontera INC. | $137.14 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Allergan, INC. | $136.60 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $105.11 | 2019-2025 | Cabtreo, Jublia |
| Botanix Sb INC | $66.51 | 2025 | Sofdra |
| Celgene Corporation | $58.15 | 2019 | |
| Journey Medical Corporation | $47.84 | 2022 | |
| Genentech USA, INC. | $33.46 | 2019-2021 | |
| Medimetriks Pharmaceuticals, INC. | $27.95 | 2025 | Clindacin Etz, Neo-Synalar |
| Sanofi-Aventis U.S. LLC | $24.97 | 2020 | |
| Cipher Pharmaceuticals US LLC | $23.53 | 2025 | Natroba, Spinosad |
| Nabriva Therapeutics, Plc | $18.70 | 2020 | |
| Aclaris Therapeutics, INC. | $14.91 | 2019 | |
| Encore Dermatology INC. | $14.56 | 2020 | |
| Leo Pharma INC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.